LogFAQs > #941073166

Still think ATHX is a steal at this price, so if you're considering getting in, it's still okay to do it now. Just don't be rattled if it ends up being $0.10 cheaper or more expensive for a while. But it's a long term stock. If you just wanna flip it for some quick cash you probably missed the window (though I expect it to eventually get to around the $2.70-$3.20 range it was at a while ago in a few days), though I do think if the BARDA thing goes through you're looking at a doubling real quick I figure.

Anyway for the record, doing some more looking into it with a weekend of people digging, it appears that the massive drop was from a New York Times article saying BARDA would not be supporting COVID treatments going forward, only vaccines. (combined with a lot of people hitting limit sells and it snowballing)

However as I understand it BARDA is only saying they're removing COVID specific treatments from the equation, and as such a more generalized thing like ATHX's multistem wouldn't be affected as it's not really a COVID specific research as much as something that is getting more attention due to COVID. It's mostly for treating ARDS (something bad cases of COVID can cause) and strokes at the moment.

(also BARDA funding isn't really necessary for the stock's long term viability, though it is something that could make it have a temporary surge)

---

No problem!
This is a cute and pop genocide of love!